Gone are the days of Covid-19 vaccine developers promising to quickly shift their mRNA vaccines to target the next variant every three to four months.
Now, CBER Director Peter Marks is calling on the Modernas and BioNTech/Pfizers of the world to really start considering to develop a “distinctly improved generation of SARS-CoV-2 vaccines offering longer protection with greater scope.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.